Skip to main content

Advertisement

Table 2 Thromboembolic events by dabigatran dose and each factor

From: Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration

Factor Thromboembolism (+) (n = 18) Thromboembolism (−) (n = 683) ODDS ratio [95% CI], (P-value)
Very low-dose (75 mg twice daily) 3 23 5.73 [1.55–21.2], (0.009*)
Age, years 77.4 ± 13.5 71.0 ± 10.8 1.06 [1.01–1.12], (0.013*)
Gender, female 10 234 2.40 [0.93–6.16], (0.069)
Creatinine clearance: Ccr (mL/min) 58.9 ± 23.5 69.0 ± 25.3 0.98 [0.96–1.02], (0.096)
History of bleeding 1 78 0.46 [0.06–3.45], (0.449)
New users 8 346 1.28 [0.50–3.29], (0.604)
Change from warfarin 8 224 1.66 [0.65–4.27], (0.292)
C: Congestive heart failure 6 132 1.84 [0.67–4.99], (0.233)
H: Hypertension 9 417 0.56 [0.22–1.45], (0.231)
A: Aged 75 or older 13 281 3.16 [1.11–8.96], (0.031*)
D: Diabetes Mellitus 5 135 1.36 [0.47–3.90], (0.561)
S: Stroke/TIA (2 points) 10 175 3.24 [1.26–8.36], (0.015*)
CHADS2 score 2.94 ± 1.51 1.92 ± 1.34 1.69 [1.21–2.37], (0.002*)
With antiplatelet agents 2 127 0.55 [0.12–2.43], (0.426)
  1. *P < 0.05